Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about MS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
🤖 AI-GeneratedNo AI portrait yet
| Associated Genes | AB, ACHE, ACSL4, AD, AGING, ALZHEIMER, ALZHEIMER'S DISEASE, AMYLOID |
| KG Connections | 550 knowledge graph edges |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
Knowledge base pages for this entity
graph TD
MS["MS"] -->|"causes"| DEMYELINATION["DEMYELINATION"]
style DEMYELINATION fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#e0e0e0
MS["MS"] -->|"causes"| NEURODEGENERATION["NEURODEGENERATION"]
style NEURODEGENERATION fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#e0e0e0
MS["MS"] -->|"causes"| AXONAL_DAMAGE["AXONAL_DAMAGE"]
style AXONAL_DAMAGE fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#e0e0e0
MS["MS"] -->|"regulates"| CNS["CNS"]
style CNS fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
MS["MS"] -->|"associated"| OXPCS["OXPCS"]
style OXPCS fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
MS["MS"] -->|"causes"| NEUROINFLAMMATION["NEUROINFLAMMATION"]
style NEUROINFLAMMATION fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#e0e0e0
MS["MS"] -->|"causes"| STING["STING"]
style STING fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
STING_1["STING"] -->|"implicated in"| MS["MS"]
style STING_1 fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
SPINK5["SPINK5"] -->|"associated"| MS["MS"]
style SPINK5 fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#e0e0e0
STS["STS"] -->|"associated"| MS["MS"]
style STS fill:#1a2a3a,stroke:#ce93d8,stroke-width:1px,color:#e0e0e0
B_cells["B cells"] -->|"associated"| MS["MS"]
style B_cells fill:#1a2a3a,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
INFLAMMATION_1["INFLAMMATION_1"] -->|"causes"| MS["MS"]
style INFLAMMATION_1 fill:#1a2a3a,stroke:#ffd54f,stroke-width:1px,color:#e0e0e0
style MS fill:#ef5350,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0,font-weight:bold| Target | Relation | Type | Str |
|---|---|---|---|
| NEURODEGENERATION | causes | phenotype | 1.00 |
| DEMYELINATION | causes | phenotype | 1.00 |
| diseases-ms | has_wiki | wiki | 1.00 |
| AXONAL_DAMAGE | causes | phenotype | 0.79 |
| OXPCS | associated_with | protein | 0.72 |
| CNS | regulates | brain_region | 0.72 |
| NEUROINFLAMMATION | causes | phenotype | 0.72 |
| STING | causes | protein | 0.72 |
| neurodegeneration | associated_with | phenotype | 0.72 |
| BRAIN_ATROPHY | causes | phenotype | 0.64 |
| AXONAL_LOSS | causes | phenotype | 0.64 |
| Apoptosis | therapeutic_target | pathway | 0.60 |
| Innate Immunity | activates | pathway | 0.60 |
| Phagocytosis | therapeutic_target | pathway | 0.60 |
| Blood-Brain Barrier | therapeutic_target | pathway | 0.60 |
| Glycolysis | interacts_with | pathway | 0.60 |
| Akt | activates | pathway | 0.60 |
| Complement | associated_with | pathway | 0.60 |
| Wnt | interacts_with | pathway | 0.60 |
| Endocytosis | interacts_with | pathway | 0.60 |
| Oxidative Phosphorylation | interacts_with | pathway | 0.60 |
| Complement | activates | pathway | 0.60 |
| Pi3K | interacts_with | pathway | 0.60 |
| Blood-Brain Barrier | interacts_with | pathway | 0.60 |
| Mtor | interacts_with | pathway | 0.60 |
| Pi3K | expressed_in | pathway | 0.60 |
| Nf-Κb | activates | pathway | 0.60 |
| Innate Immunity | inhibits | pathway | 0.60 |
| Mitochondrial Function | interacts_with | pathway | 0.60 |
| Immune Response | activates | pathway | 0.60 |
| Circadian Rhythm | interacts_with | pathway | 0.60 |
| Circadian Rhythm | regulates | pathway | 0.60 |
| Oxidative Stress | regulates | pathway | 0.60 |
| Immune Response | inhibits | pathway | 0.60 |
| Calcium Signaling | regulates | pathway | 0.60 |
| Mapk | associated_with | pathway | 0.60 |
| Mitophagy | associated_with | pathway | 0.60 |
| Sleep-Wake | regulates | pathway | 0.60 |
| Oxidative Phosphorylation | activates | pathway | 0.60 |
| Unfolded Protein Response | activates | pathway | 0.60 |
| Mtor | activates | pathway | 0.60 |
| Apoptosis | regulates | pathway | 0.60 |
| Cholesterol | activates | pathway | 0.60 |
| Nf-Κb | inhibits | pathway | 0.60 |
| Pyroptosis | therapeutic_target | pathway | 0.60 |
| Angiogenesis | activates | pathway | 0.60 |
| Pi3K | therapeutic_target | pathway | 0.60 |
| Apoptosis | activates | pathway | 0.60 |
| Akt | expressed_in | pathway | 0.60 |
| Akt | interacts_with | pathway | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| diseases-ms | described_by | wiki | 1.00 |
| SPINK5 | associated_with | gene | 0.80 |
| B cells | associated_with | cell_type | 0.80 |
| STS | associated_with | gene | 0.80 |
| STING | implicated_in | protein | 0.80 |
| INFLAMMATION_1 | causes | phenotype | 0.72 |
| S1P receptors | implicated_in | receptor | 0.70 |
| gut microbiota | associated_with | process | 0.70 |
| ACSL4 | associated_with | protein | 0.70 |
| S1P | implicated_in | entity | 0.70 |
| CD19 | biomarker_for | protein | 0.70 |
| REST | inhibits | gene | 0.65 |
| PAFAH1B1 | interacts_with | gene | 0.65 |
| SLC16A2 | therapeutic_target | gene | 0.65 |
| JUN | regulates | gene | 0.65 |
| DAB1 | interacts_with | gene | 0.65 |
| RAB7A | regulates | gene | 0.65 |
| H3F3A | biomarker_for | gene | 0.65 |
| LIS1 | interacts_with | gene | 0.65 |
| HCN4 | inhibits | gene | 0.65 |
| HCN1 | inhibits | gene | 0.65 |
| HCN2 | inhibits | gene | 0.65 |
| HCN1 | expressed_in | gene | 0.65 |
| HCN1 | activates | gene | 0.65 |
| HCN4 | regulates | gene | 0.65 |
| HCN2 | regulates | gene | 0.65 |
| JUN | therapeutic_target | gene | 0.65 |
| CDK5 | interacts_with | gene | 0.65 |
| SLC16A1 | therapeutic_target | gene | 0.65 |
| IDH1 | therapeutic_target | gene | 0.65 |
| VEGFA | therapeutic_target | gene | 0.65 |
| BMAL1 | expressed_in | gene | 0.65 |
| JUN | inhibits | gene | 0.65 |
| TERT | therapeutic_target | gene | 0.65 |
| SMARCA4 | therapeutic_target | gene | 0.65 |
| SRC | regulates | gene | 0.65 |
| DCX | interacts_with | gene | 0.65 |
| JUN | associated_with | gene | 0.65 |
| EEF1A1 | therapeutic_target | gene | 0.65 |
| MCL1 | therapeutic_target | gene | 0.65 |
| TIGAR | activates | gene | 0.65 |
| IDH2 | activates | gene | 0.65 |
| GAIN | activates | gene | 0.65 |
| TKT | activates | gene | 0.65 |
| IDH2 | associated_with | gene | 0.65 |
| IDH1 | biomarker_for | gene | 0.65 |
| TERT | biomarker_for | gene | 0.65 |
| JUN | biomarker_for | gene | 0.65 |
| CIC | biomarker_for | gene | 0.65 |
| FUBP1 | biomarker_for | gene | 0.65 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
molecular neurobiology | 2026-04-25 | 28 hypotheses Top: 0.865
neurodegeneration | 2026-04-15 | 1 hypotheses Top: 0.734
neuroinflammation | 2026-04-13 | 2 hypotheses Top: 0.453
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple sys [PMID:9682846] | Unknown | Neuroscience letters | 1998 | 0 |
| Mutation in the alpha-synuclein gene identified in families with Parkinson's dis [PMID:9197268] | Unknown | Science (New York, N.Y.) | 1997 | 0 |
| Alpha-synuclein in Lewy bodies. [PMID:9278044] | Unknown | Nature | 1997 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.66 · 2026-04-25
closed · Rounds: 4 · Score: 0.75 · 2026-04-16
closed · Rounds: 4 · Score: 0.68 · 2026-04-14
closed · Rounds: 4 · Score: 0.62 · 2026-04-14
closed · Rounds: 4 · Score: 0.92 · 2026-04-14
Hypotheses and analyses mentioning MS in their description or question text
Score: 0.638 · neurodegeneration · 2026-04-04
## Molecular Mechanism and Rationale The molecular foundation for acid-degradable lipid nanoparticle (ADP-LNP)-mediated
Score: 0.626 · neurodegeneration · 2026-04-28
mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inflammatory signaling should produce a mea
Score: 0.615 · neurodegeneration · 2026-04-21
**Molecular Mechanism and Rationale** The mitochondria-associated ER membranes (MAMs) represent specialized microdomain
Score: 0.612 · neurodegeneration · 2026-04-28
The question is likely underpowered or misleading unless analyses preserve the key strata: FUS, FUS-, ALS, NMJ. Averagin
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro
Score: 0.608 · neurodegeneration · 2026-04-28
The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a pro